Reunion Unlocks Full RE104 PPD Phase 2 Trial Results
Reunion Neuroscience’s single-dose RE104 met the primary endpoint in the Phase 2 RECONNECT study for postpartum depression (PPD), delivering...
FDA Confirms Rexlemestrocel-L Efficacy for Back Pain Relief
Mesoblast’s first randomized Phase 3 trial in chronic discogenic low back pain reported a more than three-fold increase in...
Axsome Launches Surging Phase 3 Trial for Fibromyalgia Drug
Axsome has dosed the first patient in FORWARD, a Phase 3 randomized withdrawal trial of AXS-14 (esreboxetine) for fibromyalgia....
VapeAway Begins Clinical Study for Vaping Cessation Device
VapeAway has enrolled the first participant in CONQUER, a single‑arm, open‑label, multicenter study of its drug‑free filter and Fix+Bar...
Pioneering Phase 3 Prostate Cancer Study Doses First Patient
Telix has dosed the first U.S. patient in BiPASS, a prospective, open-label Phase 3 study evaluating whether adding 68Ga-PSMA-11...
Krystal Biotech Confirms CFTR Delivery in Phase 1 CF Study
In the highest-dose cohort of its Phase 1 CORAL-1 study, Krystal’s inhaled gene therapy KB407 achieved confirmed airway transduction...
COACH Trial Confirms Durable Benefits in Achondroplasia
Topline at 52 weeks from Ascendis’ Phase 2 COACH study in pediatric achondroplasia showed mean annualized growth velocity of...
Benitec BB-301 Trial Shows Positive Long-Term Efficacy
Topline data: In Benitec’s Phase 1b/2a OPMD study, the first treated patient showed sustained and deepening benefit at 24...
Phase 1 Trial of AGENT-797 to Prevent Graft-vs-Host Disease
MiNK Therapeutics will open an investigator-sponsored Phase 1 trial of its off-the-shelf iNKT cell therapy, agenT-797, in allogeneic hematopoietic...
Marius Pharma to Study Kyzatrex in Men Ages 65-80
In its prior Phase 3 program, KYZATREX achieved normal 24-hour mean total testosterone levels in 88% of treated hypogonadal...